Drugs / cross-linked hyaluronic acid

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT07520539 Jul → Dec 2026 expected gingival recession Cairo University Not yet recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05429229 Nov 2021 → Dec 2023 diabetic retinopathy, disorder of defective peroxisome oxidative status, dry eye syndrome Adolfo Daniel Rodriguez-Carrizalez Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT06517667 Nov 2023 → Feb 2024 dry eye syndrome University of Seville Completed No outcome recorded
Phase not applicable1 trial
NCT05727371 Aug 2023 → Feb 2026 overdue osteoarthritis, knee RegenLab France SAS Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT07715331 Comparator Jan 2025 → Feb 2026 gingival disorder Al-Azhar University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Cross-Linked Hyaluronic Acid “It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol...” NCT05429229
4

“combination of cross-linked hyaluronic acid (HA) with autologous platelet-rich plasma (PRP) obtained with the RegenMatrix medical device” NCT05727371

“Tear substitute based on 0.20% Cross-linked hyaluronic acidNCT06517667

NCT07715331

NCT07520539

Known as Juvéderm Voluma with Lidocaine “cross-linked hyaluronic acid filler (Juvéderm Voluma® with Lidocaine)” NCT07715331
Route Topical “preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid” NCT05429229